Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth qua ...More

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This contrasts with Rs 1,222 crore reported in the same period last year. The company's Board has recommended a final dividend of Rs 13 per share for the fiscal year ending March 2026. ...Less

Cipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financi ...More

Cipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also declined. Despite these figures, key therapies and trade generics business showed strong growth. The company plans to focus on expanding its markets and developing its future pipeline. A final dividend of Rs 13 per equity share has been recommended. ...Less

Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages ...More

Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despite a weak Q4 performance. The stock hit an intraday high of Rs 1,432.10 as investors focused on future growth prospects over near-term earnings pressure. ...Less

Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income ...More

Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income also saw a 3% decrease. For the full financial year, revenue grew slightly by 2%, but profit after tax declined by 26%. The company's MD highlighted strong performance in key therapy areas and sustained growth in its generics and consumer health businesses. ...Less

Domestic equities rallied for a second day on Thursday, with banks, metals and pharma powering gains even ...More

Domestic equities rallied for a second day on Thursday, with banks, metals and pharma powering gains even as IT lagged, while several major stocks saw sharp moves on earnings and announcements. ...Less

TVS Motor Q4 Results: TVS Motor posted a strong Q4FY26 with net profit up 19% to Rs 772 crore and revenue ...More

TVS Motor Q4 Results: TVS Motor posted a strong Q4FY26 with net profit up 19% to Rs 772 crore and revenue rising 30% to Rs 15,053 crore. Overall sales grew 28% to 15.6 lakh units, driven by robust motorcycle, scooter and EV volumes, even as profit dipped sequentially. ...Less

The Board has also recommended the payment of a final dividend of Rs 8.50 per equity share for the financ ...More

The Board has also recommended the payment of a final dividend of Rs 8.50 per equity share for the financial year ended March 2023. ...Less

The total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the com ...More

The total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quarter. ...Less

Cipla Q4 Results: The company’s revenue from operations grew by 8.45% year-on-year to Rs 6,597.72 crore, ...More

Cipla Q4 Results: The company’s revenue from operations grew by 8.45% year-on-year to Rs 6,597.72 crore, compared to Rs 6,082.37 crore in the corresponding quarter of the previous fiscal ...Less

Cipla Q4 Results: Revenue from operations increased 7% year-on-year to Rs 6,163 crore in the March quarte ...More

Cipla Q4 Results: Revenue from operations increased 7% year-on-year to Rs 6,163 crore in the March quarter. EBITDA for the quarter under review increased 13% year-on-year to Rs 1,316 crore as against 1166 crore in the last year period. ...Less

Cipla's North America sales, which constitute primarily US, grew 11.8% YoY to Rs 1875 crore driven by key ...More

Cipla's North America sales, which constitute primarily US, grew 11.8% YoY to Rs 1875 crore driven by key products Lanreotide (used for treating growth hormone disorder) gaining market share to 20.8% and 12-13% Albuterol (anti-asthma inhalation) coupled with robust demand in base business. ...Less

The company’s consolidated revenues for the quarter rose 5.2 per cent on-year to Rs. 4,606.45 crore, whic ...More

The company’s consolidated revenues for the quarter rose 5.2 per cent on-year to Rs. 4,606.45 crore, which was also sharply below Street’s estimate. ...Less

Total income of the company stood at Rs 3,737.9 crore, up 3.69 per cent YoY. ...More

Total income of the company stood at Rs 3,737.9 crore, up 3.69 per cent YoY. ...Less

In Q4, North America delivered strong growth of 41 per cent YoY and 38 per cent QoQ. ...More

In Q4, North America delivered strong growth of 41 per cent YoY and 38 per cent QoQ. ...Less

Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of th ...More

Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarter surging by as much as 71% year-on-year, alongside an expected 7% year-on-year increase in net sales. ...Less

The profit figure was better than Rs 320 crore estimated by analysts in an ET Now poll. ...More

The profit figure was better than Rs 320 crore estimated by analysts in an ET Now poll. ...Less

Phillip Capital expects 8.1 per cent YoY growth in net profit of Cipla. ...More

Phillip Capital expects 8.1 per cent YoY growth in net profit of Cipla. ...Less

Q4 results today: Several other companies scheduled to release their financial results include Cholamanda ...More

Q4 results today: Several other companies scheduled to release their financial results include Cholamandalam Finance, Eicher Motors, Finolex Industries, Jupiter LifeLine Hospitals, Kalyan Jewellers, Piramal Pharma, Punjab and Sind Bank, Spencers Retail, TCI Express, Thermax, and more. ...Less

The company, aspiring to become a lung leader globally, could not escape the impact of coronavirus. ...More

The company, aspiring to become a lung leader globally, could not escape the impact of coronavirus. ...Less

The profit figure missed ET NOW poll estimate of Rs 355 crore. ...More

The profit figure missed ET NOW poll estimate of Rs 355 crore. ...Less

However, the profit figure managed to beat Rs 601 crore figure anticipated by analysts in an ET NOW poll. ...More

However, the profit figure managed to beat Rs 601 crore figure anticipated by analysts in an ET NOW poll. An ET NOW poll had anticipated the profit figure at Rs 601 crore. ...Less

Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore ...More

Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period. ...Less

The management expects the impact of COVID-19 to be short-lived and has guided for a recovery in the near ...More

The management expects the impact of COVID-19 to be short-lived and has guided for a recovery in the near term. ...Less

Cipla's June quarter earnings are anticipated to reveal a mixed performance, with robust India sales part ...More

Cipla's June quarter earnings are anticipated to reveal a mixed performance, with robust India sales partially offsetting challenges in the US generics market. Revenue is expected to increase, while EBITDA margins may decline due to lower US contributions. Investor attention will be directed towards the US business trajectory, pricing dynamics, and the resurgence of India's trade generics segment. ...Less

Q2 earnings for Maruti and Cipla are expected to be muted, with Maruti likely seeing a 2% decline in volu ...More

Q2 earnings for Maruti and Cipla are expected to be muted, with Maruti likely seeing a 2% decline in volumes and flat revenues, while net profit could drop up to 5%. Cipla may report 3-6% revenue growth and a 4-5.7% rise in net profit. ...Less

Cipla Q1 Results: Cipla reported a 10% YoY increase in consolidated net profit, reaching Rs 1,298 crore f ...More

Cipla Q1 Results: Cipla reported a 10% YoY increase in consolidated net profit, reaching Rs 1,298 crore for the June quarter, driven by a 4% rise in revenue from operations to Rs 6,957 crore. EBITDA stood at Rs 1,778 crore, reflecting a slight margin dip to 25.6%. The company's profit before tax reached Rs 1,770 crore. ...Less

Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenu ...More

Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company saw strong performance in its India and North America businesses, with key products like Foracort and Albuterol leading. ...Less

Bank of Baroda posted a modest 2% YoY rise in Q1 FY26 profit to ₹4,541 crore. Net interest income dipped ...More

Bank of Baroda posted a modest 2% YoY rise in Q1 FY26 profit to ₹4,541 crore. Net interest income dipped 1.4%, impacted by tax refund reclassification. Deposits and advances, both domestic and international, grew strongly year-on-year. ...Less

Shriram Finance Q1 Results: The profit after tax (PAT) increased slightly by 0.8% quarter-on-quarter comp ...More

Shriram Finance Q1 Results: The profit after tax (PAT) increased slightly by 0.8% quarter-on-quarter compared to ₹2,139 crore in Q4FY25, while net interest income (NII) declined marginally by 0.41% sequentially from ₹6,051 crore in the same period. ...Less

Motilal Oswal Q3 Results: Motilal Oswal Financial Services (MOFSL) reported a 14% YoY decline in Q3FY25 n ...More

Motilal Oswal Q3 Results: Motilal Oswal Financial Services (MOFSL) reported a 14% YoY decline in Q3FY25 net profit to ₹565 crore despite a 12% rise in revenue. Sequentially, PAT dropped 50%, while segment performance showed mixed trends. ...Less

The dismal numbers from the drugmaker weighed on the stock, which extended the day’s losses and hit an ov ...More

The dismal numbers from the drugmaker weighed on the stock, which extended the day’s losses and hit an over 4-month low of Rs 1,021. The shares were trading 3.2% lower on the National Stock Exchange at Rs 1,028.45. ...Less

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacte ...More

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Revenue remained flat at Rs 7,074 crore, with EBITDA also declining. The company plans upcoming launches to offset revenue decline and drive future growth. ...Less

Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, E ...More

Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, ESAF SFB, Equitas SFB, Mangalam Organics, Piramal Pharma, TTK Prestige among others will also declare their results. ...Less